AnaptysBio Inc (ANAB)
21.17
+0.86
(+4.23%)
USD |
NASDAQ |
Nov 21, 16:00
21.18
+0.02
(+0.07%)
After-Hours: 20:00
AnaptysBio Revenue (Quarterly): 30.02M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 30.02M |
| June 30, 2024 | 10.97M |
| March 31, 2024 | 7.179M |
| December 31, 2023 | 9.005M |
| September 30, 2023 | 3.318M |
| June 30, 2023 | 3.46M |
| March 31, 2023 | 1.374M |
| December 31, 2022 | 6.808M |
| September 30, 2022 | 1.293M |
| June 30, 2022 | 1.216M |
| March 31, 2022 | 0.97M |
| December 31, 2021 | 1.011M |
| September 30, 2021 | 20.89M |
| June 30, 2021 | 30.03M |
| March 31, 2021 | 11.25M |
| December 31, 2020 | 60.00M |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | 15.00M |
| December 31, 2019 | 3.00M |
| September 30, 2019 |
| Date | Value |
|---|---|
| June 30, 2019 | 5.00M |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | 5.00M |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | 3.00M |
| September 30, 2017 | |
| June 30, 2017 | 7.00M |
| March 31, 2017 | |
| December 31, 2016 | 2.754M |
| September 30, 2016 | 3.214M |
| June 30, 2016 | 5.85M |
| March 31, 2016 | 4.866M |
| December 31, 2015 | 4.054M |
| September 30, 2015 | 4.538M |
| June 30, 2015 | 4.882M |
| March 31, 2015 | 4.097M |
| December 31, 2014 | 3.705M |
| September 30, 2014 | 6.154M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.97M
Minimum
Mar 2022
60.00M
Maximum
Dec 2020
12.04M
Average
6.994M
Median
Revenue (Quarterly) Benchmarks
| Eli Lilly and Co | 11.44B |
| Regeneron Pharmaceuticals Inc | 3.721B |
| Ligand Pharmaceuticals Inc | 51.81M |
| Agios Pharmaceuticals Inc | 8.964M |
| ADMA Biologics Inc | 119.84M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -32.85M |
| Total Expenses (Quarterly) | 52.77M |
| EPS Diluted (Quarterly) | -1.14 |
| Enterprise Value | 214.06M |
| Profit Margin (Quarterly) | -109.4% |
| Earnings Yield | -28.72% |
| Normalized Earnings Yield | -28.72 |